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OBJECTIVES This study evaluated the causes of syncope and the significance and differences in left
ventricular (LV) dysfunction, coronary disease, and idiopathic dilated cardiomyopathy
(DCM).
BACKGROUND Risk stratification of and indications for an automated defibrillator could differ according to
the cause of LV dysfunction.
METHODS Electrophysiologic study, including atrial and ventricular programmed stimulation, was
performed in 119 patients with coronary disease (group I) and 61 patients with DCM (group
II) with an left ventricular ejection fraction (LVEF) 40% and syncope. Patients were
followed from one to six years (mean 4  2 years).
RESULTS Sustained monomorphic ventricular tachycardia (VT) was induced in 44 group I patients
(37%) and 13 group II patients (21%); ventricular flutter (270 beats/min) or ventricular
fibrillation (VF) was induced in 24 group I patients (19%) and 9 group II patients (15%); and
various other arrhythmias were identified. Syncope remained unexplained in 34 group I
patients (30%) and 16 group II patients (27%). Prognosis depended on the heart disease: VT
or VF induction was a predictive factor of mortality in coronary disease and identified a group
with high cardiac mortality (46%), compared with patients with a negative study, who had a
lower mortality (6%; p  0.001) than in other studies. Cardiac mortality was only correlated
with LVEF in DCM.
CONCLUSIONS Various causes could explain syncope in 70% of patients with coronary disease and DCM, but
differences were noted: VT was frequent in coronary disease with a bad prognosis, and
ischemia could explain syncope; in DCM, different causes such as atrial tachycardia could be
responsible for syncope, but the prognosis only depended on LVEF. (J Am Coll Cardiol
2004;44:594–601) © 2004 by the American College of Cardiology Foundationt
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wyncope is reported as a clinical sign of high risk of sudden
eath in patients with left ventricular (LV) dysfunction
1,2). In the era of the implantable cardioverter-defibrillator
ICD) (3–5), establishing the etiology of syncope is partic-
larly important. We know that the causes of syncope are
ultiple (6) and that the implantation of an ICD does not
esolve all causes of syncope and cardiac death (7). Studies
n the prognosis of patients with syncope and heart failure
HF) have generally included patients with several etiolo-
ies. According to the nature of heart disease, the mecha-
ism of syncope, its prognosis, and the methods used to
valuate risk stratification could differ. If indications for
CD now are clear in coronary disease and decreased LV
jection fraction (LVEF), they are still debatable in idio-
athic dilated cardiomyopathy (DCM) (8). Electrophysi-
logic study (EPS) actually remains the best means to
tratify patients with heart disease (9,10).
Therefore, the purposes of the study were to evaluate: 1)
From the Department of Cardiology, CHU of Brabois, Vandoeuvre Les Nancy,
rance. This study was presented at the 75th Scientific Sessions of the American
eart Association, November 2002, Chicago, IL.
Manuscript received September 23, 2003; revised manuscript received February 20,p004, accepted March 2, 2004.he possible mechanisms of syncope; 2) the results of EPS;
nd 3) the prognosis of patients, according to the mecha-
ism of LV dysfunction (i.e., idiopathic DCM or coronary
isease).
tudy population. All patients with coronary disease and
V dysfunction and those with idiopathic DCM who had
n LVEF 40%, unexplained syncope (n  121), or
izziness and at least one episode of syncope (n  98),
efined as a short loss of consciousness, were systematically
ecruited between 1985 and the beginning of 2000.
Patients were excluded from the study if they had: 1)
nstable angina; 2) recent acute myocardial infarction (MI)
1 month); 3) recent coronary angioplasty or coronary
ypass surgery (6 weeks); 4) paroxysmal second- or
hird-degree atrioventricular (AV) block on presentation; 5)
ustained supraventricular or ventricular arrhythmia on pre-
entation; 6) clinical HF not controlled by furosemide; 7)
ncontrolled electrolytical abnormalities; 8) significant non-
ardiac disease; or 9) received long-term amiodarone treat-
ent.
During the period of study, 219 patients were recruited, of
hom 37 had at least one exclusion criterion. Two additional
atients were excluded because they were lost to follow-up.
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August 4, 2004:594–601 Syncope in Ischemic and Idiopathic CardiomyopathyThe remaining 180 patients were classified into two
roups according to their history and results of coronary
ngiography: 1) Group I comprised 119 patients who had
oronary disease with a history of MI and/or multiple
oronary stenoses on coronary angiography and an LVEF
40% (range 10% to 40%, mean 29 7%). There were 101
ales and 18 females (age range 25 to 80 years, mean 65 
1.5 years). 2) Group II comprised 61 patients who had
diopathic DCM confirmed by a normal coronary angio-
ram. The angiographic LVEF varied from 10% to 40%
mean 27  10%; p  NS). There were 52 males and 9
emales (age range 27 to 78 years, mean 62  10 years).
tudy protocol. Patients underwent several investigations
n the absence of anti-arrhythmic drugs after giving written,
nformed consent. A personal and familial clinical history,
ist of drugs taken at the time of syncope, and clinical
xamination were noted.
The studies were performed in patients in stable clinical
onditions after adaptation of their treatment. Most patients
eceived angiotensin-converting enzyme inhibitors. Beta-
lockers and digoxin were stopped before EPS.
The following noninvasive studies were performed: 24-h
olter monitoring (Elatec, France), two-dimensional echo-
ardiography, thallium exercise scintigraphy in patients with
schemic heart disease and no recent coronary angiography
n  10) or with significant coronary artery stenosis on
oronary angiography (n  16), and head-up tilt testing
ithout provocative drugs in 30 patients with a negative
PS or inducible ventricular flutter or ventricular fibrillation
VF).
The following invasive studies were performed: right and
eft angiography, coronary angiography, and a complete
PS study according to a protocol previously reported
11,12).
The protocol included assessment of sinoatrial function,
V conduction using measurement of the AH and HV
ntervals and intra-atrial conduction time, and atrial pacing
t progressively faster rates until AV block occurred.
Programmed atrial stimulation was performed during
inus rhythm and paced cycle lengths (600 and 400 ms).
ne and two extrastimuli were delivered. Right ventricular
Abbreviations and Acronyms
AV  atrioventricular
BP  blood pressure
DCM  dilated cardiomyopathy
EPS  electrophysiologic study
HF  heart failure
ICD  implantable cardioverter-defibrillator
LV  left ventricular
LVEF  left ventricular ejection fraction
MI  myocardial infarction
SVTA  supraventricular tachyarrhythmia
VF  ventricular fibrillation
VT  ventricular tachycardiaacing was performed up to 200 beats/min. Programmed iight ventricular stimulation using one and two extrastimuli
ere introduced during sinus rhythm and paced cycle
engths (600 and 400 ms) at the apex and subsequently at
he outflow tract. A third extrastimulus was added if
ustained ventricular tachycardia (VT) or VF was not
nduced. Short coupling intervals (200 ms) were not used.
If the study remained negative, the protocol was repeated
fter isoproterenol infusion at a dose of 2 to 4 g/min to
ecrease the sinus cycle length by at least 15% (13).
Arterial blood pressure (BP) was continuously monitored
y an external sphygmomanometer (Baxter, Hayash-
komaki, Japan). Carotid sinus massage was performed until
he development of the head-up tilt test (1992).
Abnormal electrophysiologic findings were categorized
ccording to the following diagnostic criteria:
Sinus node dysfunction was considered as present if the
corrected sinus node recovery time (sinus recovery time
mean sinus cycle length) was 550 ms.
Conduction disturbances were present if AV Wenck-
ebach block occurred at a pacing rate of 90 beats/min,
if the HV interval was60 ms in the case of right bundle
branch block and 70 ms in the case of left bundle
branch block, and if infrahisian second-degree AV block
occurred at a pacing rate 150 beats/min.
Hypervagotonia was present if carotid sinus massage
produced an asystole with an RR interval of 3,000 ms.
Inducible supraventricular tachyarrhythmia (SVTA) was
defined as a sustained (3 min), either spontaneously
regressive but reproducible or permanent SVTA provo-
cating a drop in arterial BP (30%) and symptoms
similar to dizziness, which could be a paroxysmal junc-
tional tachycardia or atrial tachyarrhythmia (atrial tachy-
cardia, flutter, or fibrillation). The induction of a rela-
tively slow atrial fibrillation without symptoms or
changes in BP was considered as not pathologic. When
sustained VT was also induced, the presumed cause of
syncope was categorized as ventricular tachyarrhythmias.
Inducible ventricular tachyarrhythmias were categorized
as: 1) monomorphic VT (270 beats/min) lasting more
than 30 s or requiring termination because of hemody-
namic intolerance or lasting between 10 and 30 s and
responsible for syncope; or 2) ventricular flutter (270
beats/min) or VF requiring cardioversion to stop it.
ollow-up. Patients were followed from one to six years
mean 4  2) or until heart transplantation (n  6). The
atient was examined by the referent doctor every month
nd one of our cardiologists every three months. The
ollow-up was stopped at six years, because the hemody-
amic and coronary status may have changed after this
eriod.
A pacemaker was implanted in patients with conduction
isturbances. In those who also had inducible VT, anti-
rrhythmic therapy was introduced after pacemaker implan-
ation, or since 1998, a pacemaker and defibrillator were
mplanted.
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Syncope in Ischemic and Idiopathic Cardiomyopathy August 4, 2004:594–601Patients with induced SVTA or VT were treated with a
ombination of 200 mg amiodarone and small doses of a
eta-blocker. This treatment was electrophysiologically
uided. In the last recruited patients and in those with still
apid inducible VT, an ICD was placed. Before 1998, VT
adiofrequency catheter ablation was performed in five
atients; in patients receiving anti-arrhythmic drugs, the
T became not inducible or slowed and was hemodynam-
cally well tolerated.
In patients with a non-arrhythmic cause of syncope such
s ischemia, a specific treatment was indicated.
We considered the total cardiac mortality, including
eaths related to HF and sudden deaths. “Sudden death”
as defined as an unexpected death from a cardiac cause
ithin a short period (1 h); deaths associated with the
evelopment of spontaneous VT were classified with sudden
eaths. Two deaths occurring during the night in stable
atients were classified as sudden deaths. Some deaths
ccurred in our hospital; for those who died at home or in
nother hospital, we contacted the last medical doctor and
he family to classify the mode of death.
Figure 1. General Kaplan-Meier survival
Table 1. Clinical and Electrophysiological Dat
HF De
(n  1
Age (yrs) 70 
Female gender 3 (17%
NSVT/Holter monitor 9 (50%
LVEF (%) 29 
Induced monomorphic VT/VF (n  68) 16 (23.
Induced monomorphic VT (n  44) 10 (55.
Induced VF (n  24) 6 (33%
Negative study (n  51) 2 (11%
Comparisons with alive patients: *p  0.05. †p  0.01. ‡p 
of patients.
HF  heart failure; LVEF  left ventricular ejection
ventricular flutter/fibrillation; VT  ventricular tachycardia 270tatistical analysis. Data are expressed as the mean value
SD. Statistical analysis was performed using the unpaired
tudent t test for quantitative data and the chi-square test
or discrete variables and ordinal tests. A p value 0.05 was
onsidered as significant. Stepwise logistic regression anal-
sis was performed to identify the independent variables
redictive of cardiac death. The predictive negative and
ositive values of the data of programmed ventricular
timulation to predict cardiac death were calculated. Sur-
ival curves were calculated using the Kaplan Meier
roduct-limit method and compared by the log-rank test.
ESULTS
esults of EPS. Sustained monomorphic VT (from 160 to
69 beats/min, mean 210) or syncopal nonsustained VT
frequency from 220 to 240 beats/min) was induced in 44
roup I patients (37%) and 13 group II patients (21%; p 
S). There was no bundle branch tachycardia.
Ventricular flutter or fibrillation was induced in 24
s for groups I (1) and II (2) (p  NS).
Group I
Sudden Death
(n  16)
Total Deaths
(n  34)
Alive
(n  85)
65  10 68  12 65  12
1 (6%) 4 (12%) 14 (16%)
9 (56%) 18 (53%) 30 (35%)
29  7 29  7 30  7
15 (22%) 31* (91%) 37 (43.5%)
13† (81%) 23‡ (68%) 19 (22%)
2 (12.5%) 8 (23.5%) 16 (19%)
1 (6%) 3 (9%) 48 (56%)
. Data are presented as the mean value  SD or number (%)
n; NSVT  nonsustained ventricular tachycardia; VF a on
ath
8)
13
)
)
7
5%)
5%)
)
)
0.001
fractio
beats/min.
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 NS).
In group I, ventricular tachyarrhythmia was induced by
ne extrastimulus (n  13) and two (n  35) and three
xtrastimuli (n  20) in the control state in 64 patients and
fter isoproterenol in four patients. In group II, ventricular
achyarrhythmia was induced by two (n  10) or three
xtrastimuli (n  12) in the control state in 18 patients and
fter isoproterenol in four patients. In addition, SVTA was
nduced in 11 group I patients (9%) and 15 group II patients
25%; p  0.001).
Conduction disturbances were noted in three group I
atients (2.5%) and five group II patients (8%). Infrahisian
igure 2. Kaplan-Meier survival curves for group I patients according to th
patients with a negative study; lower line  patients with induced ven
igure 3. Kaplan-Meier survival curves according to the results of programm
ine  patients with a negative study; middle line  patients with induc
achycardia [VT]).onduction abnormalities were also noted in association
ith inducible VT in seven group I patients (6%) and one
roup II patient (2%).
Carotid sinus massage was positive in three group I
atients and two group II patients, but other arrhythmias
ere noted, and hypervagotonia was not retained as the
ause of syncope.
The EPS remained negative in 43 group I patients (36%)
nd 20 group II patients (33%; p  NS).
esults of other investigations. 24-H HOLTER MONITOR-
NG. Ventricular arrhythmias (couplets or nonsustained
T) were present in 54 group I patients (45%) and 25 group
I patients (41%; p  NS).
lts of programmed ventricular stimulation (VS) (p  0.0009) (upper line
ar tachycardia [VT] and ventricular fibrillation [VF]).
entricular stimulation (VS) in group I (log-rank 13.92, p 0.0009) (upper
tricular fibrillation [VF]; lower line  patients with induced ventriculare resued v
ed ven
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Syncope in Ischemic and Idiopathic Cardiomyopathy August 4, 2004:594–601EAD-UP TILT TEST. In 30 patients, this test reproduced
he syncope in four group I patients with a negative EPS
nd two group I patients with inducible ventricular flutter.
yncope was reproduced in three group II patients with a
egative EPS.
HALLIUM-201 EXERCISE SCINTIGRAPHY. This modality
howed severe coronary ischemia (40%) with a drop in
rterial BP and/or development of polymorphic VT in three
roup I patients.
At the end of investigations, syncope remained unex-
lained in 34 group I patients (30%) and 16 group II
atients (27%; p  NS).
ollow-up (1 to 6 years, mean 4  2 years). The general
urvival was 65% at five years, similar in both groups
log-rank 0.76; p  NS) (Fig. 1).
In group I, an ICD was placed in four patients. Heart
ransplantation was performed in three patients. Thirty-four
atients died of a cardiac cause: 18 from HF and 16
uddenly; among the latter group, two were resuscitated but
ied of HF one year later. Sudden deaths occurred between
wo weeks and one year after the hospitalization for syn-
ope. One sudden death occurring during Holter monitor-
ng was related to VT degenerating into VF; this patient
ad inducible monomorphic VT. Deaths related to HF
ccurred between one month and five years after syncope.
Among alive patients, six had recurrent syncope and a
econd EPS. In four of them, both studies remained
egative; they are alive. In two patients, sustained VT was
nduced on both studies; one patient died later from HF and
n ICD was placed in the other one.
Among the 11 patients with SVTA, none died suddenly.
able 2. Positive and Negative Predictive Values of the
nduction of Monomorphic Ventricular Tachycardia 270
eats/min and Ventricular Fibrillation to Predict All Cardiac
eaths, Sudden Death, and Death Related to Heart Failure in
roup I
PPV NPV
CD SD HF CD SD HF
T 52% 29.5% 23% 85% 96% 89%
F 33% 8% 25% 73% 85% 87%
D  cardiac death; HF  heart failure; NPV  negative predictive value; PPV 
ositive predictive value; SD  sudden death; VF  ventricular fibrillation/flutter;
T  ventricular tachycardia.
Table 3. Clinical and Electrophysiologic Data
HF Death
(n  5)
Age (yrs) 68  6
Female gender 1 (20%)
NSVT/Holter monitor 4
LVEF (%) 23  8
Induced VT/VF (n  22) 1(20%)
Negative study (n  39) 4 (80%)
*p  0.05. Data are presented as the mean value  SD or n
Abbreviations as in Table 1.ne patient developed AV node reentrant tachycardia, and
hree had paroxysmal rapid atrial fibrillation.
Table 1 reports the results of noninvasive and invasive
tudies in group I according to follow-up. The LVEF and
resence of salvos of ventricular premature beats were similar in
live patients and those who died. There was a trend toward
lder age in patients who died compared with alive patients,
ut the differences were not significant. There was a higher
otal cardiac mortality (46%) in patients with inducible ven-
ricular tachyarrhythmias than in those with a negative EPS
6%; p 0.001). Induced VT was significantly associated with
eath from HF (p 0.05) and sudden death (p 0.01). The
ignificance of induced flutter/fibrillation remained unclear
ecause the differences were not significant; linear logistic
egression shows that it was only a significant predictor of total
ardiac mortality (odds ratio 3.406), but it was not a significant
redictor of sudden death. Survival curves indicated a high
ifference of mortality rates in patients with inducible ventric-
lar tachyarrhythmias as compared with those with a negative
tudy (Fig. 2) (log-rank 11.08, p  0.0009). Significant
ifferences were noted in patients with inducible VT or those
ith inducible ventricular flutter/fibrillation, as compared with
hose with negative programmed stimulation (Fig. 3) (log-rank
3.92, p  0.0009).
The positive and negative values of the induction of VT or
nother arrhythmia for the prediction of death are reported in
able 2. The positive predictive value is relatively low, but the
egative predictive value is high. The positive predictive value
f a negative programmed ventricular stimulation to predict
urvival is high; its negative predictive value is lower.
In group II, an ICD was placed in three patients. Heart
ransplantation was performed in three patients. Ten patients
ied of a cardiac cause, HF (n  5), or sudden death (n  5).
mong the patients who died suddenly, four had inducible
entricular arrhythmias, syncopal nonsustained VT (n 1), or
entricular flutter (n  3).
Two patients with a negative study but a positive head-up
ilt test still had dizziness.
In the 15 patients with SVTA who are still alive, two
eveloped AV node reentrant tachycardia, two had atrial
utter, and three developed chronic atrial fibrillation.
Table 3 reports the results of studies in group II patients
ccording to their follow-up. There was a trend toward a
ore frequent presence of salvos of ventricular beats on
roup II
den Death
(n  5)
Total Deaths
(n  10)
Alive
(n  51)
49  15 58.5  14 62  11
3 (60%) 5 (50%) 7 (14%)
3 7 17 (33%)
25  14 24  11* 29  7
4 (80%) 5 (50%) 17 (33%)
1 (20%) 5 (50%) 34 (67%)
r (%) of patients.on G
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August 4, 2004:594–601 Syncope in Ischemic and Idiopathic Cardiomyopathyolter monitoring in those who died than in alive patients,
ut the differences were not statistically significant. The
nly significant difference was LVEF, which was lower in
atients dead from a cardiac cause than in alive patients
p  0.05). There is a trend for a higher frequency of
nducible ventricular tachyarrhythmia to predict sudden
eath, but the cardiac mortality was statistically similar in
atients with inducible VT or ventricular flutter (23%) and
n those with a negative EPS (13%). Kaplan-Meier survival
urves did not reveal significant differences of cardiac
ortality according to the induction or not of ventricular
achyarrhythmias (log-rank 2.64, p  NS) (Fig. 4). How-
ver, the survival curve of patients with inducible ventricular
igure 4. Kaplan-Meier survival curves according to the results of progra
atients with a negative study; lower line  patients with induced ventric
igure 5. Kaplan-Meier survival curves for group II patients according to th
negative study and inducible ventricular tachycardia [VT]; lower line  indutter/fibrillation differed significantly from that of the
emaining population (log-rank 11.13, p 0.0038) (Fig. 5).
The positive predictive value of the induction of ventric-
lar tachyarrhythmia to predict all types of death is low, but
ts negative predictive value is high (Table 4). The positive
alue of a negative programmed ventricular stimulation to
redict patient survival is high, but its negative predictive value
s lower.
ISCUSSION
he study confirms that syncope is a clinical sign of
eleterious prognosis in patients with LV dysfunction and
ventricular stimulation (VS) in group II (NS, p  0.10) (upper line 
achycardia [VT] and ventricular fibrillation [VF]).
lts of programmed ventricular stimulation (VS) (p 0.0038) (upper linesmmede resu
ucible ventricular fibrillation [VF]).
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Syncope in Ischemic and Idiopathic Cardiomyopathy August 4, 2004:594–601nducible monomorphic VT (14–16) In fact, this is a strong
rognostic factor for mortality in coronary disease and a
eaker factor in idiopathic DCM. The high mortality in
oronary disease was previously reported (17). The signifi-
ance of inducible ventricular flutter/fibrillation is more
ebatable. It is considered as without clinical significance in
symptomatic, post-MI patients (11,18) and in those with
yncope and coronary disease, as reported by Mitall et al.
19). In the present study, we noted a higher cardiac
ortality than in those with a negative study, but the deaths
ould be related to HF and the differences were not
tatistically significant. A negative EPS in patients with
oronary disease, syncope, and LVEF 40% indicates a
rognosis similar to that of a population without syncope
11). The relatively low mortality is probably explained by
he date of MI, which is frequently old. Most sudden deaths
ccur during the first year after acute MI.
Menozzi et al. (20) reported that the causes of syncope in
oronary disease are multiple. Vagal hypertonia could be a
requent cause (21–23), and paroxysmal AV block was also
requent (24,25).
In patients with idiopathic DCM, abnormal electrophysi-
logic data were noted with a similar incidence as in patients
ith coronary disease, but SVTA could be a more frequent
nding than VT. This cause remains difficult to prove;
alvos of atrial premature beats on 24-h Holter monitoring
re frequent and not specific, but the relationships between
yncope and SVTA were previously demonstrated (26). The
rognosis was independent of the results of the EPS and the
resence of syncope; a control group without syncope had a
ardiac mortality rate of 18% at three years (13). The
ortality is lower than in epidemiologic studies of patients
dmitted for HF (27–29), because our patients were in a
table hemodynamic condition, as in asymptomatic patients
30). The present study indicated that a low LVEF was the
nly significant predictor of death in this disease.
tudy limitations. The small number of patients with an
CD could explain the high mortality of patients with
oronary disease, syncope, and induced ventricular tachyar-
hythmia. This is explained by the period of recruitment, as
he indications for ICD in France were rare. Anti-
rrhythmic drugs did not explain the high mortality, because
e have used amiodarone, which has been demonstrated
ithout a negative effect in MI, and beta-blockers, which
ave beneficial effects. The EPS was performed in the
upine position; only the patients with rapid nonsustained
able 4. Positive and Negative Predictive Values of Positive
rogrammed Ventricular Stimulation (VT and VF) to Predict
otal Cardiac Death, Sudden Death, and Death Related to
eart Failure in Group II
PPV NPV
CD SD HF CD SD HF
T/VF 23% 18% 4.5% 87% 97% 90%
bbreviations as in Table 2.onomorphic VT reproduced their syncope. The head-upilt testing was not systematic, and some neurocardiogenic
yncope could have been missed. The number of patients
ith syncope and idiopathic DCM is relatively small, and
ome data have shown a low statistical significance.
onclusions. The presumed causes of syncope were iden-
ified with the same frequency in patients with coronary
isease and LV dysfunction and those with idiopathic
CM, but SVTA could be a more frequent cause of
yncope in idiopathic DCM, and ventricular tachyarrhyth-
ias could be more frequent in coronary disease. The
rognosis differed and was dependent on the results of EPS
rincipally in coronary disease with a high spontaneous
ardiac mortality in patients with induced ventricular tachy-
rrhythmias. The prognosis mainly depended on LVEF in
diopathic DCM.
eprint requests and correspondence: Dr. Be´atrice Brembilla-
errot, Cardiologie, CHU de Brabois, 54500 Vandoeuvre Les
ancy, France. E-mail: b.brembilla-perrot@chu-nancy.fr.
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